Page 70 - Demo

from symptomatic SARS-CoV-2 infection. Nat Med.2021;27(7):1205-11.39. Pollard AJ, Bijker EM. A guide to vaccinology: frombasic principles to new developments. Nat RevImmunol. 2021;21(2):83-100.40. Luo M, Liu J, Jiang W, Yue S, Liu H, Wei S. IL-6 andCD8+ T cell counts combined are an earlypredictor of in-hospital mortality of patients withCOVID-19. JCI Insight. 2020;5(13).41. Diao B, Wang C, Tan Y, Chen X, Liu Y, Ning L, et al.Reduction and Functional Exhaustion of T Cells inPatients With Coronavirus Disease 2019 (COVID19). Front Immunol. 2020;11:827.42. Hellerstein M. What are the roles of antibodies versusa durable, high quality T-cell response inprotective immunity against SARS-CoV-2? VaccineX. 2020;6:100076.43. Brien JD, Uhrlaub JL, Nikolich-Zugich J. West Nilevirus-specific CD4 T cells exhibit direct antiviralcytokine secretion and cytotoxicity and aresufficient for antiviral protection. J Immunol.2008;181(12):8568-75.44. Boyd A, Almeida JR, Darrah PA, Sauce D, Seder RA,Appay V, et al. Correction: Pathogen-Specific TCell Polyfunctionality Is a Correlate of T CellEfficacy and Immune Protection. PLoS One.2015;10(9):e0138395.45. Mayr LM, Su B, Moog C. Non-Neutralizing AntibodiesDirected against HIV and Their Functions. FrontImmunol. 2017;8:1590.46. Bootz A, Karbach A, Spindler J, Kropff B, Reuter N,Sticht H, et al. Protective capacity of neutralizingand non-neutralizing antibodies againstglycoprotein B of cytomegalovirus. PLoS Pathog.2017;13(8):e1006601.47. Carragher DM, Kaminski DA, Moquin A, Hartson L,Randall TD. A novel role for non-neutralizingantibodies against nucleoprotein in facilitatingresistance to influenza virus. J Immunol.2008;181(6):4168-76.27. Thomas SJ, Perez JL, Lockhart SP, Hariharan S, KitchinN, Bailey R, et al. Efficacy and safety of theBNT162b2 mRNA COVID-19 vaccine in participantswith a history of cancer: subgroup analysis of aglobal phase 3 randomized clinical trial. Vaccine.2022;40(10):1483-92.28. Ahmed A, Nezami M, Alkattan A. Pitfalls at Chemistryof Adenoviral Vector Vaccine against COVID-19 andHow to Circumvent it. Adv Pharm Bull.2022;12(2):217-8.29. He Q, Mao Q, Peng X, He Z, Lu S, Zhang J, et al.Immunogenicity and protective efficacy of arecombinant protein subunit vaccine and aninactivated vaccine against SARS-CoV-2 variants innon-human primates. Signal Transduct TargetTher. 2022;7(1):69.30. Gurunathan S, Klinman DM, Seder RA. DNA vaccines:immunology, application, and optimization*. AnnuRev Immunol. 2000;18:927-74.31. Waltz E. Omicron-targeted vaccines do no better thanoriginal jabs in early tests. Nature. 2022.32. Mallapaty S. India%u2019s DNA COVID vaccine is a world first- more are coming. Nature. 2021;597(7875):161-2.33. Malone B, Urakova N, Snijder EJ, Campbell EA.Structures and functions of coronavirusreplication-transcription complexes and theirrelevance for SARS-CoV-2 drug design. Nat Rev MolCell Biol. 2022;23(1):21-39.34. Grifoni A, Sidney J, Zhang Y, Scheuermann RH, PetersB, Sette A. A Sequence Homology andBioinformatic Approach Can Predict CandidateTargets for Immune Responses to SARS-CoV-2. CellHost Microbe. 2020;27(4):671-80 e2.35. Gil-Etayo FJ, Garcinuno S, Utrero-Rico A, CabreraMarante O, Arroyo-Sanchez D, Mancebo E, et al.An Early Th1 Response Is a Key Factor for aFavorable COVID-19 Evolution. Biomedicines.2022;10(2).36. Guti%u00e9rrez-Bautista JF, Rodriguez-Nicolas A, RosalesCastillo A, Jimenez P, Garrido F, Anderson P, et al.Negative Clinical Evolution in COVID-19 Patients IsFrequently Accompanied With an IncreasedProportion of Undifferentiated Th Cells and aStrong Underrepresentation of the Th1 Subset.Front Immunol. 2020;11:596553.37. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al.Clinical features of patients infected with 2019novel coronavirus in Wuhan, China. Lancet.2020;395(10223):497-506.38. Khoury DS, Cromer D, Reynaldi A, Schlub TE,Wheatley AK, Juno JA, et al. Neutralizing antibodylevels are highly predictive of immune protection192ANALESRANFwww.analesranf.coman. R. acad. Farm.vol. 91. n%u00ba2 (2025) %u00b7 pp. 173-192The non-replicative DNA vaccine, pPAL-S + pPAL-N,free of antibiotic resistance genes, confers completeprotection in mice against SARS-CoV-2Pedro J. Alcolea, Jaime Larraga et al.Si desea citar nuestro art%u00edculo:la vacuna no replicativa de adN, pPal-S + pPal-N,libre de genes de resistencia a antibi%u00f3ticos, confiereprotecci%u00f3n completa en ratones frente al SaRS-Cov-2Pedro J. Alcolea, Jaime Larraga, Ana Alonso, FranciscoJ. Loayza, Jos%u00e9 M. Rojas y Ver%u00f3nica Mart%u00edn,Noem%u00ed Sevilla, Vicente Larraga An Real Acad Farm (Internet).An. Real Acad. Farm.Vol. 91. n%u00ba 2 (2025) %u00b7 pp. 173-192DOI:http://dx.doi.org/10.53519/analesranf.2025.91.02.03